

RESEARCH PAPER



3*H*-1,2-benzoxathiepine 2,2-dioxides: a new class of isoform-selective carbonic anhydrase inhibitors

Aleksandrs Pustenko^{a,b}, Dmitrijs Stepanovs^a, Raivis Žalubovskis^a, Daniela Vullo^c, Andris Kazaks^d, Janis Leitans^d, Kaspars Tars^e and Claudiu T. Supuran^f

^aLatvian Institute of Organic Synthesis, Riga, Latvia; ^bInstitute of Technology of Organic Chemistry, Faculty of Materials Science and Applied Chemistry, Riga Technical University, Riga, Latvia; ^cDipartimento di Chimica, Laboratorio di Chimica Bioinorganica, Polo Scientifico, Università degli Studi di Firenze, Sesto Fiorentino, Florence, Italy; ^dLatvian Biomedical Research and Study Centre, Riga, Latvia; ^eFaculty of Biology, Department of Molecular Biology, University of Latvia, Riga, Latvia; ^fDipartimento Neurofarba, Sezione di Scienze Farmaceutiche e Nutraceutiche, Università degli Studi di Firenze, Sesto Fiorentino, Florence, Italy

ABSTRACT

A new chemotype with carbonic anhydrase (CA, EC 4.2.1.1) inhibitory action has been discovered, the homo-sulfocoumarins (3*H*-1,2-benzoxathiepine 2,2-dioxides) which have been designed considering the (sulfo)coumarins as lead molecules. An original synthetic strategy of a panel of such derivatives led to compounds with a unique inhibitory profile and very high selectivity for the inhibition of the tumour associated (CA IX/XII) over the cytosolic (CA I/II) isoforms. Although the CA inhibition mechanism with these new compounds is unknown for the moment, we hypothesize that it may be similar to that of the sulfo-coumarins, i.e. hydrolysis to the corresponding sulfonic acids which thereafter anchor to the zinc-coordinated water molecule within the enzyme active site.

ARTICLE HISTORY

Received 15 March 2017
Revised 1 April 2017
Accepted 4 April 2017

KEYWORDS

Carbonic anhydrase;
sulfocoumarin; homo-
sulfocoumarins; inhibitor

Introduction

Sulfocoumarins (1,2-benzoxathiine 2,2-dioxides) such as derivatives of type **A** were discovered by our groups to act as inhibitors of the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1)^{1,2}. A large series of sulfocoumarins derivatives, among which compounds of type **B**, were thereafter reported, by using click chemistry or other conventional drug design approaches (Figure 1)^{3–6}.

A salient feature of this type of CA inhibitor (CAI) was the fact that they showed a very pronounced isoform selectivity for inhibiting tumour-associated CA isoforms (CA IX and XII) over the widespread, cytosolic ones CA I and II^{1–3}. This has been explained when the mechanism of CA inhibition with sulfocoumarins was elucidated, by using kinetic and X-ray crystallographic experiments¹. Indeed, in the X-ray crystal structure of the adduct of a CA II/IX mimic complexed with the 6-bromosulfocoumarin **A2** (**A**, R = Br) (Figure 1), the 2-dihydroxy-5-bromophenyl-vinyl sulfonic acid **D** was observed within the enzyme active site, probably due to the CA-mediated hydrolysis of **A2** to the *cis*-sulfonic acid **C** which was thereafter isomerized to the more stable *trans*-derivative **D** (Scheme 1)¹.

This inhibition mechanism is similar to the one observed earlier for coumarins^{7,8} the class of CAIs which constituted the lead compounds for the discovery of sulfocoumarins. Finding isoform-selective CAIs for the 15 different human CA isoforms is a challenging task^{9,10}, but coumarins and sulfocoumarins (and several families of sulfonamides) do show such properties, which make them of great interest for the design of pharmacological agents useful as diuretics, antiglaucoma, anticonvulsant and/or antitumor drugs^{9–13}.

Here, we report the homo-sulfocoumarins or 3*H*-1,2-benzoxathiepine 2,2-dioxides, which can be considered as homologs of

sulfocoumarins or 1,2-benzoxathiine 2,2-dioxides¹, where oxathiine ring was expanded by one carbon to form an oxathiepine ring. To the best of our knowledge, there is no reported method for the synthesis of 3*H*-1,2-benzoxathiepine 2,2-dioxides in the literature. The general strategy for the formation of oxathiepine ring reported in this paper involves a ruthenium-catalysed olefin metathesis as a key step.

Materials and methods

Chemistry

Reagents, starting materials and solvents were obtained from commercial sources and used as received. Thin-layer chromatography was performed on silica gel, spots were visualized with UV light (254 and 365 nm). Melting points were determined on an OptiMelt automated melting point system. IR spectra were measured on Shimadzu FTIR IR Prestige-21 spectrometer. NMR spectra were recorded on Varian Mercury (400 MHz) spectrometer with chemical shifts values (δ) in ppm relative to TMS using the residual DMSO- d_6 signal (¹H 2.50; ¹³C 39.52) or CDCl₃ signal (¹H 7.26; ¹³C 77.16) as an internal standard. HRMS data were obtained with a Q-TOF micro high resolution mass spectrometer with ESI (ESI+/ESI). Elemental analyses were performed on a CARLO ERBA ELEMENTAL ANALYZER EA 1108.

General procedure for the synthesis of 4-substituted 2-ethenylphenoles (2a–c)¹⁴

To a stirred solution of methyltriphenylphosphonium bromide (2.64 eq.) in dry THF (5 ml/1 mmol of corresponding aldehyde),

was added tBuOK (2.86–3.12 eq.) in several portions over 20 min. Reaction mixture was stirred for 1 h at RT. Corresponding 2-hydroxy benzaldehyde (1 eq.) was added and stirring continued at room temperature for 24 h. Reaction mixture was diluted with CH₂Cl₂ (5 ml/1 mmol aldehyde). Organic layer was collected and washed with water (2 × 20 ml) and brine (2 × 20 ml), dried over Na₂SO₄, solvent was driven off in vacuum. The crude product was purified by column chromatography (silica gel, EtOAc/PhMe 1:5).

2-Ethenylphenol (2a)

Compound **2a** was prepared according to the general procedure from methyltriphenylphosphonium bromide (18.88 g, 52.9 mmol), tBuOK (6.42 g, 57.2 mmol) and 2-hydroxybenzaldehyde (2.44 g, 20.0 mmol) as yellowish at room temperature melting solid (1.67 g, 70%). ¹H NMR (400 MHz, CDCl₃) δ = 5.37 (dd, 1H, *J* = 11.3, 1.3 Hz), 5.42 (s, 1H), 5.76 (dd, 1H, *J* = 17.8, 1.3 Hz), 6.81 (dd, 1H, *J* = 8.1, 1.1 Hz), 6.90–6.96 (m, 1H), 6.98 (dd, 1H, *J* = 17.8, 11.3 Hz), 7.12–7.18 (m, 1H), 7.41 (dd, 1H, *J* = 7.7, 1.7 Hz).

4-Bromo-2-ethenylphenol (2b)

Compound **2b** was prepared according to the general procedure from methyltriphenylphosphonium bromide (13.22 g, 37.0 mmol), tBuOK (4.90 g, 43.7 mmol) and 5-bromo-2-hydroxybenzaldehyde (2.81 g, 14.0 mmol) as yellowish at room temperature melting solid (1.64 g, 59%). ¹H NMR (400 MHz, CDCl₃) δ = 4.98 (s, 1H), 5.40 (dd, 1H, *J* = 11.3, 1.0 Hz), 5.74 (dd, 1H, *J* = 17.8, 1.0 Hz), 6.68 (d, 1H, *J* = 8.6 Hz), 6.85 (dd, 1H, *J* = 17.8, 8.6 Hz), 7.23 (dd, 1H, *J* = 8.6, 2.4 Hz), 7.49 (d, 1H, *J* = 2.4 Hz).

2-Ethenyl-4-nitrophenol (2c)

Compound **2c** was prepared according to the general procedure from methyltriphenylphosphonium bromide (28.31 g, 79.3 mmol), tBuOK (9.60 g, 85.6 mmol) and 5-nitro-2-hydroxybenzaldehyde (5 g, 30 mmol) as yellow at room temperature melting solid (3.23 g, 65%). ¹H NMR (400 MHz, CDCl₃) δ = 5.43 (dd, 1H, *J* = 11.3, 1.1 Hz), 5.87 (dd, 1H, *J* = 17.8, 1.1 Hz), 6.92–7.00 (m, 2H), 7.96 (dd, 1H, *J* = 8.9, 2.6 Hz), 8.31 (d, 1H, *J* = 2.6 Hz), 8.82 (s, 1H).

Prop-2-ene-1-sulfonyl chloride (3)¹⁵

To a solution of 3-bromoprop-1-ene (24.2 g, 0.20 mol) in water (140 ml) was added Na₂SO₃ (30 g, 0.24 mol) and the reaction

mixture was refluxed overnight. After cooling to room temperature, reaction mixture was washed with Et₂O (3 × 35 ml). Aqueous phase was concentrated. Crude white solid was dried under high vacuum at 110 °C for 4 h. To the white solid at 0 °C POCl₃ (80 ml) was added, and mixture was refluxed for 4 h. After cooling to room temperature dry THF (60 ml) was added and reaction mixture was vigorously stirred for 10 min and filtered. Filter cake was suspended in dry THF (60 ml), suspension was vigorously stirred for 10 min and filtered. Filtrates were combined and solvent was carefully driven off on rotary evaporator. Residue was distilled in vacuum (10 mbar) and fraction with boiling point 38–42 °C was collected, to give prop-2-ene-1-sulfonyl chloride (**3**) as colourless oil (18.8 g, 67%).

General procedure for the synthesis of 4-substituted 2-ethenyl prop-2-ene-1-sulfonates (4a–c)

To a stirred solution of corresponding 2-ethenylphenol **2** (1 eq.) in CH₂Cl₂ (10 ml/20 mmol phenol) at 0 °C was added prop-2-ene-1-sulfonyl chloride (**3**) (1.6 eq.) and Et₃N (1.5 eq.). Reaction mixture was stirred overnight (20 h) at room temperature. Water (10 ml/20 mmol phenol) was added, reaction mixture was extracted with EtOAc (3 × 10 ml/20 mmol phenol), combined organic extracts were washed with brine (2 × 10 ml/20 mmol olefin), dried over Na₂SO₄, filtered and solvent was driven off in vacuum. The crude product was purified by column chromatography (silica gel, CH₂Cl₂/PhMe 3:2).

2-Ethenylphenyl prop-2-ene-1-sulfonate (4a)

Compound **4a** was prepared according to the general procedure from 2-ethenylphenol (**2a**) (0.50 g, 4.16 mmol), prop-2-ene-1-sulfonyl chloride (**3**) (0.94 g, 6.69 mmol) and Et₃N (0.87 ml, 6.23 mmol) as colourless oil (0.52 g, 56%). IR (film, cm⁻¹) ν_{max} = 1368 (S=O), 1178 (S=O), 1154 (S=O); ¹H NMR (400 MHz, CDCl₃) δ = 3.96–4.00 (m, 2H), 5.37–5.41 (m, 1H), 5.48–5.54 (m, 2H), 5.79 (dd, 1H, *J* = 17.6, 0.9 Hz), 5.90–6.01 (m, 1H), 6.99 (dd, 1H, *J* = 17.6, 11.0 Hz), 7.23–7.34 (m, 2H), 7.57–7.62 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ = 55.6, 117.3, 122.8, 123.9, 125.4, 126.9, 127.4, 129.2, 130.3, 131.3, 146.5; HRMS (ESI) *m/z* [M – 1]⁻ calcd for C₁₁H₁₁O₃S: 223.0429, found 223.0435.

4-Bromo-2-ethenylphenyl prop-2-ene-1-sulfonate (4b)

Compound **4b** was prepared according to the general procedure from 4-bromo-2-ethenylphenol (**2b**) (0.50 g, 2.51 mmol), prop-2-ene-1-sulfonyl chloride (**3**) (0.57 g, 4.05 mmol) and Et₃N (0.52 ml, 3.76 mmol) as colourless oil (0.51 g, 67%). IR (film, cm⁻¹) ν_{max} = 1364 (S=O), 1170 (S=O), 1154 (S=O); ¹H NMR (400 MHz, CDCl₃) δ = 4.00 (dt, 2H, *J* = 7.4, 0.9 Hz), 5.46 (d, 1H, *J* = 11.0 Hz), 5.51–5.59 (m, 2H), 5.81 (d, 1H, *J* = 17.6 Hz), 5.91–6.03 (m, 1H), 6.92 (dd, 1H, *J* = 17.6, 11.0 Hz), 7.22 (d, 1H, *J* = 8.6 Hz), 7.41 (dd, 1H, *J* = 8.6, 2.4 Hz), 7.73 (d, 1H, *J* = 2.4 Hz); ¹³C NMR (100 MHz, CDCl₃) δ = 55.7, 118.6, 121.0, 123.7, 124.6, 125.7, 129.2, 129.8, 132.0, 133.3,





Figure 1. Chemical structure of sulfocoumarins A and B.



Scheme 1. Active site, CA-mediated hydrolysis of A2 to D¹.


145.3; HRMS (ESI) m/z $[M - 1]^-$ calcd for $C_{11}H_{10}BrO_3S$: 300.9534, found 300.9537.

2-Ethenyl-4-nitrophenyl prop-2-ene-1-sulfonate (4c)

Compound **4c** was prepared according to the general procedure from 2-ethenyl-4-nitrophenol (**2c**) (0.32 g, 1.94 mmol), prop-2-ene-1-sulfonyl chloride (**3**) (0.44 g, 3.13 mmol) and Et_3N (0.41 ml, 2.96 mmol) as yellowish oil (0.30 g, 57%). IR (film, cm^{-1}) ν_{max} = 1350 (S=O), 1159 (S=O); 1H NMR (400 MHz, $CDCl_3$) δ = 4.01 (dt, 2H, J = 7.2, 0.9 Hz), 5.54–5.63 (m, 3H), 5.93–6.05 (m, 2H), 6.99 (dd, 1H, J = 17.6, 11.0 Hz), 7.53 (d, 1H, J = 9.0 Hz), 8.16 (dd, 1H, J = 9.0, 2.8 Hz), 8.48 (d, 1H, J = 2.8 Hz); ^{13}C NMR (100 MHz, $CDCl_3$) δ = 56.3, 120.2, 122.4, 123.4, 123.8, 124.0, 126.2, 128.6, 132.8, 146.5, 150.2; HRMS (ESI) m/z $[M - 1]^-$ calcd for $C_{11}H_{10}NO_5S$: 268.0280, found 268.0280.


General procedure for the synthesis of 7-substituted 3H-1,2-benzoxathiepine 2,2-dioxides (6a–c)

To a stirred solution of corresponding 4-substituted 2-ethenyl prop-2-ene-1-sulfonate (1 eq.) in dry toluene (10 ml/0.2 g **4**), was added Ru-catalyst **5** (tricyclohexylphosphine[1,3-bis(2,4,6-trimethylphenyl)imidazol-2-ylidene][3-phenyl-1H-inden-1-ylidene]ruthenium(II) dichloride, CAS Nr. 254972–49-1) (0.05 eq.). Reaction mixture was stirred at 70 °C for 4 h. Solvent was driven off in vacuum and the crude product was purified by column chromatography (silica gel, Hex/EtOAc 4:1) with following re-crystallization from EtOAc/Hex. Compound **6c** was purified by column chromatography (silica gel, CH_2Cl_2 /Hex 2:1).



3H-1,2-benzoxathiepine 2,2-dioxide (6a)


Compound **5a** was prepared according to the general procedure from 2-ethenylphenyl prop-2-ene-1-sulfonate (**4a**) (100 mg, 0.45 mmol), Ru-catalyst **5** (21 mg, 0.022 mmol) as white solid (76 mg, 87%). Mp 131–132 °C. IR (film, cm^{-1}) ν_{max} = 1369 (S=O), 1176 (S=O); 1H NMR (400 MHz, $CDCl_3$) δ = 4.01 (dd, 2H, J = 6.3, 1.2 Hz), 5.96–6.03 (m, 1H), 6.90 (d, 1H, J = 10.9 Hz), 7.31–7.37 (m, 3H), 7.41–7.46 (m, 1H); ^{13}C NMR (100 MHz, $CDCl_3$) δ = 51.2, 119.5, 123.0, 127.3, 128.4, 130.6, 130.8, 132.9, 147.8; HRMS (ESI) m/z $[M - 1]^-$ calcd for $C_9H_7O_3S$: 195.0116, found 195.0115.



7-Bromo-3H-1,2-benzoxathiepine 2,2-dioxide (6b)


Compound **5b** was prepared according to the general procedure from 4-bromo-2-ethenylphenyl prop-2-ene-1-sulfonate (**4b**) (100 mg, 0.33 mmol), Ru-catalyst **5** (16 mg, 0.017 mmol) as yellowish solid (76 mg, 84%). Mp 129.3–130.3 °C. IR (film, cm^{-1}) ν_{max} = 1360 (S=O), 1170 (S=O), 1154 (S=O); 1H NMR (400 MHz, $CDCl_3$) δ = 4.03 (dd, 2H, J = 6.3, 0.9 Hz), 5.99–6.06 (m, 1H), 6.81 (d, 1H, J = 11.0 Hz), 7.22 (d, 1H, J = 8.6 Hz), 7.47 (d, 1H, J = 2.4 Hz), 7.54

(dd, 1H, J = 8.6, 2.4 Hz); ^{13}C NMR (100 MHz, $CDCl_3$) δ = 51.4, 120.5, 120.9, 124.7, 130.2, 131.6, 133.5, 133.6, 146.7; Anal. Calcd for $C_9H_7BrO_3S$ (275.12): C 39.29, H 2.56, found C 39.19, H 2.59.




7-Nitro-3H-1,2-benzoxathiepine 2,2-dioxide (6c)

Compound **5c** was prepared according to the general procedure from 2-ethenyl-4-nitrophenyl prop-2-ene-1-sulfonate (**4c**) (100 mg, 0.37 mmol), catalyst **5** (18 mg, 0.019 mmol) as yellowish solid (86 mg, 96%). Mp 130–131 °C. IR (film, cm^{-1}) ν_{max} = 1375 (S=O), 1351 (S=O), 1170 (S=O), 1161 (S=O); 1H NMR (400 MHz, $CDCl_3$) δ = 4.18 (dd, 2H, J = 5.8, 1.2 Hz), 6.05–6.12 (m, 1H), 6.89 (d, 1H, J = 11.3 Hz), 7.48 (d, 1H, J = 8.9 Hz), 8.24 (d, 1H, J = 2.6 Hz), 8.28 (dd, 1H, J = 8.9, 2.6 Hz); ^{13}C NMR (100 MHz, $CDCl_3$) δ = 52.4, 121.6, 124.3, 125.6, 126.8, 129.4, 130.8, 151.3; Anal. Calcd for $C_9H_7NO_5S$ (241.22): C 44.81, H 2.92, N 5.81, found C 44.70, H 2.95, N 5.79.



7-Amino-3H-1,2-benzoxathiepine 2,2-dioxide (7)

To a solution of 7-nitro-3H-1,2-benzoxathiepine 2,2-dioxide (**6c**) (250 mg, 1.04 mmol) in EtOH (4.3 ml) and H_2O (2.8 ml) AcOH (0.06 ml, 1.04 mmol) was added following by iron powder (350 mg, 6.27 mmol) at room temperature. Resulting suspension was stirred at 75 °C for 1 h. It was cooled to room temperature, EtOAc (50 ml) was added and washed with sat. aq. $NaHCO_3$ (5×30 ml). Organic layer was dried over Na_2SO_4 and concentrated in vacuum. Re-crystallized of the crude product from EtOAc/Hex afforded **7** (220 mg, 98%) as yellowish solid. Mp 170–171 °C. IR (film, cm^{-1}) ν_{max} = 3465 (N–H), 3382 (N–H), 1358 (S=O), 1163 (S=O); 1H NMR (400 MHz, $CDCl_3$) δ = 3.72–3.85 (br s, 2H), 3.92 (dd, 2H, J = 6.3, 1.0 Hz), 5.93–6.00 (m, 1H), 6.53 (d, 1H, J = 2.9 Hz), 6.68 (dd, 1H, J = 8.8, 2.6 Hz), 6.80 (d, 1H, J = 10.6 Hz), 7.12 (d, 1H, J = 8.8 Hz); ^{13}C NMR (100 MHz, $CDCl_3$) δ = 50.5, 115.0, 116.8, 119.8, 123.8, 133.4, 140.4, 145.5; HRMS (ESI) m/z $[M + H]^+$ calcd for $C_9H_{10}NO_3S$: 212.0381, found 212.0364.




7-Azido-3H-1,2-benzoxathiepine 2,2-dioxide (8)


To a solution of 7-amino-3H-1,2-benzoxathiepine 2,2-dioxide (**7**) (220 mg, 1.03 mmol) in trifluoroacetic acid (1.3 ml) at 0 °C, slowly was added $NaNO_2$ (80 mg, 1.12 mmol). After 30 min stirring at 0 °C, solution of NaN_3 (67 mg, 1.03 mmol) in water (3 ml) was added. Mixture was stirring at 0 °C for 1 h. Collection of solid precipitate and drying in vacuum afforded **8** (170 mg, 69%) as brown solid. IR (film, cm^{-1}) ν_{max} = 2116 (N_3), 1374 (S=O), 1369 (S=O), 1167 (S=O); 1H NMR (400 MHz, $CDCl_3$) δ = 4.01 (dd, 2H, J = 6.3, 1.2 Hz), 5.99–6.07 (m, 1H), 6.83 (d, 1H, J = 10.9 Hz), 6.94 (d, 1H, J = 2.8 Hz), 7.06 (dd, 1H, J = 8.9, 2.8 Hz), 7.32 (d, 1H, J = 8.9 Hz); ^{13}C NMR (100 MHz, $CDCl_3$) δ = 51.2, 120.5, 120.8, 120.9, 124.5, 129.8, 132.0, 139.2, 144.5.

General procedure for the synthesis of 1,4-disubstitutedtriazolyl compound (9–17)


To a solution of corresponding alkyne (1 eq.) in tBuOH/H₂O 1:1 mixture (10 ml) 7-azido-3H-1,2-benzoxathiepin-2,2-dioxide (**8**) (1 eq.), CuSO₄·5H₂O (2 eq.) and sodium ascorbate (4 eq.) were added and reaction mixture was stirred at room temperature for 10 min. AcOH (19–21 eq.) was added and mixture was stirred for additional 30 min. Solvent was driven off in vacuum and the crude product was purified by reversed phase chromatography (C-18, H₂O–MeCN gradient MeCN 10–90%).

**1-(2,2-Dioxido-3H-1,2-benzoxathiepin-7-yl)-4-phenyl-1H-1,2,3-triazole (9)**


Compound **9** was prepared according to the general procedure from phenylacetylene (13 mg, 0.13 mmol), azide **8** (30 mg, 0.13 mmol), CuSO₄·5H₂O (65 mg, 0.26 mmol), sodium ascorbate (103 mg, 0.52 mmol), AcOH (0.14 ml, 2.45 mmol) as white solid (41 mg, 95%). Mp 203–204 °C. IR (KBr, cm⁻¹) ν_{\max} =1368 (S=O), 1171 (S=O); ¹H NMR (400 MHz, DMSO-d₆) δ =4.61 (dd, 2H, *J*=5.9, 1.2 Hz), 6.09–6.16 (m, 1H), 7.02 (d, 1H, *J*=11.3 Hz), 7.37–7.43 (m, 1H), 7.48–7.54 (m, 2H), 7.63 (d, 1H, *J*=8.8 Hz), 7.92–7.97 (m, 2H), 8.04 (dd, 1H, *J*=8.8, 2.6 Hz), 8.13 (d, 1H, *J*=2.6 Hz), 9.35 (s, 1H); ¹³C NMR (100 MHz, DMSO-d₆) δ =51.7, 119.9, 121.6, 122.1, 122.7, 124.0, 125.3, 128.4, 129.1, 129.6, 130.0, 130.1, 135.0, 146.3, 147.5; HRMS (ESI) *m/z* [M + H]⁺ calcd for C₁₇H₁₄N₃O₃S: 340.0756, found 340.0755.

**4-(4-Chlorophenyl)-1-(2,2-dioxido-3H-1,2-benzoxathiepin-7-yl)-1H-1,2,3-triazole (10)**


Compound **10** was prepared according to the general procedure from 1-chloro-4-ethynylbenzene (17 mg, 0.12 mmol), azide **8** (29 mg, 0.12 mmol), CuSO₄·5H₂O (61 mg, 0.24 mmol), sodium ascorbate (97 mg, 0.49 mmol), AcOH (0.13 ml, 2.27 mmol) as yellowish solid (34 mg, 74%). Mp 191–192 °C. IR (KBr, cm⁻¹) ν_{\max} =1369 (S=O), 1356 (S=O), 1168 (S=O); ¹H NMR (400 MHz, DMSO-d₆) δ =4.61 (dd, 2H, *J*=5.9, 1.2 Hz), 6.09–6.16 (m, 1H), 7.01 (d, 1H, *J*=11.5 Hz), 7.55–7.61 (m, 2H), 7.63 (d, 1H, *J*=8.9 Hz), 7.92–7.98 (m, 2H), 8.02 (dd, 1H, *J*=8.9, 2.7 Hz), 8.11 (d, 1H, *J*=2.7 Hz), 9.38 (s, 1H); ¹³C NMR (100 MHz, DMSO-d₆) δ =51.7, 120.3, 121.6, 122.1, 122.7, 124.1, 127.0, 129.0, 129.1, 129.6, 130.1, 132.8, 135.0, 146.3, 146.4; HRMS (ESI) *m/z* [M + H]⁺ calcd for C₁₇H₁₃ClN₃O₃S: 374.0366, found 374.0366.

**1-(2,2-Dioxido-3H-1,2-benzoxathiepin-7-yl)-4-(3-methoxyphenyl)-1H-1,2,3-triazole (11)**

Compound **11** was prepared according to the general procedure from 3-ethynylanisole (17 mg, 0.13 mmol), azide **8** (30 mg, 0.13 mmol), CuSO₄·5H₂O (63 mg, 0.25 mmol), sodium ascorbate (100 mg, 0.50 mmol), AcOH (0.14 ml, 2.45 mmol) as yellowish solid (24 mg, 51%). Mp 210–211 °C. IR (KBr, cm⁻¹) ν_{\max} =1372 (S=O), 1162 (S=O); ¹H NMR (400 MHz, DMSO-d₆) δ =3.84 (s, 3H), 4.61 (dd, 2H, *J*=5.8, 1.2 Hz), 6.09–6.16 (m, 1H), 6.94–6.99 (m, 1H), 7.02 (d, 1H, *J*=11.5 Hz), 7.39–7.45 (m, 1H), 7.48–7.55 (m, 2H), 7.63 (d, 1H, *J*=8.9 Hz), 8.03 (dd, 1H, *J*=8.9, 2.7 Hz), 8.12 (d, 1H, *J*=2.7 Hz), 9.36 (s, 1H); ¹³C NMR (100 MHz, DMSO-d₆) δ =51.7, 55.2, 110.6, 114.1, 117.6, 120.1, 121.6, 122.1, 122.6, 124.0, 129.6, 130.1, 130.2, 131.4, 135.0, 146.3, 147.4, 159.8; HRMS (ESI) *m/z* [M + H]⁺ calcd for C₁₈H₁₆N₃O₄S: 370.0862, found 370.0876.


**1-(2,2-Dioxido-3H-1,2-benzoxathiepin-7-yl)-4-(4-fluorophenyl)-1H-1,2,3-triazole (12)**

Compound **12** was prepared according to the general procedure from 1-ethynyl-4-fluorobenzene (30 mg, 0.25 mmol), azide **8** (60 mg, 0.25 mmol), CuSO₄·5H₂O (126 mg, 0.50 mmol), sodium ascorbate (200 mg, 1.02 mmol), AcOH (0.28 ml, 5.05 mmol) as yellowish solid (60 mg, 66%). Mp 200–201 °C. IR (KBr, cm⁻¹) ν_{\max} =1369 (S=O), 1167 (S=O); ¹H NMR (400 MHz, DMSO-d₆) δ =4.61 (d, 2H, *J*=5.4 Hz), 6.07–6.17 (m, 1H), 7.01 (d, 1H, *J*=11.3 Hz), 7.30–7.71 (m, 2H), 7.63 (d, 1H, *J*=8.8 Hz), 7.94–8.05 (m, 3H), 8.11 (s, 1H), 9.34 (s, 1H); ¹³C NMR (100 MHz, DMSO-d₆) δ =51.7, 116.1 (d, *J*=21.9 Hz), 119.9, 121.6, 122.1, 122.7, 124.1, 126.6, 127.4 (d, *J*=8.3 Hz), 129.7, 130.1, 135.0, 146.3, 146.6, 162.1 (d, *J*=245.3 Hz); HRMS (ESI) *m/z* [M + H]⁺ calcd for C₁₇H₁₃FN₃O₃S: 358.0662, found 358.0656.

**1-(2,2-Dioxido-3H-1,2-benzoxathiepin-7-yl)-4-(4-(trifluoromethoxy)phenyl)-1H-1,2,3-triazole (13)**


Compound **13** was prepared according to the general procedure from 4-(trifluoromethoxy) phenylacetylene (40 mg, 0.21 mmol), azide **8** (50 mg, 0.21 mmol), CuSO₄·5H₂O (105 mg, 0.42 mmol), sodium ascorbate (167 mg, 0.84 mmol), AcOH (0.23 ml, 4.02 mmol) as yellowish solid (74 mg, 83%). Mp 168–169 °C. IR (film, cm⁻¹) ν_{\max} =1357 (S=O), 1166 (S=O); ¹H NMR (400 MHz, CDCl₃) δ =4.13 (dd, 2H, *J*=6.0, 1.1 Hz), 6.06–6.13 (m, 1H), 6.93 (d, 1H, *J*=11.3 Hz), 7.30–7.35 (m, 2H), 7.51 (d, 1H, *J*=8.8 Hz), 7.79 (dd, 1H, *J*=8.8, 2.5 Hz), 7.85 (d, 1H, *J*=2.5 Hz), 7.91–7.98 (m, 2H), 8.25 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ =51.8, 120.6 (q, *J*=257.9 Hz), 121.4, 121.7, 122.1, 122.9, 124.7, 127.5, 128.8, 130.0, 131.5, 135.6, 147.3,

149.5, 149.6; HRMS (ESI) m/z $[M + H]^+$ calcd for $C_{18}H_{13}F_3N_3O_4S$: 424.0579, found 424.0553.




1-(2,2-Dioxido-3H-1,2-benzoxathiepin-7-yl)-4-(3-fluorophenyl)-1H-1,2,3-triazole (14)

Compound **14** was prepared according to the general procedure from 1-ethynyl-3-fluorobenzene (25 mg, 0.21 mmol), azide **8** (50 mg, 0.21 mmol), $CuSO_4 \cdot 5H_2O$ (105 mg, 0.42 mmol), sodium ascorbate (166 mg, 0.84 mmol), AcOH (0.25 ml, 4.37 mmol) as brownish solid (56 mg, 74%). Mp 188–189 °C. IR (KBr, cm^{-1}) ν_{max} =1354 (S=O), 1175 (S=O); 1H NMR (400 MHz, DMSO- d_6) δ =4.62 (dd, 2H, J =6.0, 1.3 Hz), 6.09–6.16 (m, 1H), 7.01 (d, 1H, J =11.6 Hz), 7.20–7.26 (m, 1H), 7.52–7.60 (m, 1H), 7.64 (d, 1H, J =8.8 Hz), 7.70–7.75 (m, 1H), 7.77–7.81 (m, 1H), 8.02 (dd, 1H, J =8.9, 2.7 Hz), 8.10 (d, 1H, J =2.7 Hz), 9.42 (s, 1H); ^{13}C NMR (100 MHz, DMSO- d_6) δ =51.7, 111.9 (d, J =23.0 Hz), 115.1 (d, J =20.8 Hz), 120.7, 121.3 (d, J =2.5 Hz), 121.6, 122.1, 122.7, 124.1, 129.6, 130.0, 131.2 (d, J =8.7 Hz), 132.4 (d, J =8.4 Hz), 134.9, 146.3, 146.4, 162.6 (d, J =243.5 Hz); HRMS (ESI) m/z $[M + H]^+$ calcd for $C_{17}H_{13}FN_3O_3S$: 358.0662, found 358.0667.



2-[1-(2,2-Dioxido-3H-1,2-benzoxathiepin-7-yl)-1H-1,2,3-triazol-4-yl]aniline (15)


Compound **15** was prepared according to the general procedure from 2-ethynylaniline (25 mg, 0.21 mmol), azide **8** (50 mg, 0.21 mmol), $CuSO_4 \cdot 5H_2O$ (105 mg, 0.42 mmol), sodium ascorbate (166 mg, 0.84 mmol), AcOH (0.25 ml, 4.37 mmol) as yellowish solid (43 mg, 57%). Mp 190–191 °C. IR (film, cm^{-1}) ν_{max} =3430 (N-H), 3364 (N-H), 1365 (S=O), 1358 (S=O), 1167 (S=O), 1163 (S=O); 1H NMR (400 MHz, DMSO- d_6) δ =4.61 (dd, 2H, J =6.0, 1.2 Hz), 6.09–6.16 (m, 1H), 6.49–6.85 (m, 2H), 7.01 (d, 1H, J =11.3 Hz), 7.10–7.18 (m, 1H), 7.59–7.66 (m, 2H), 8.08 (dd, 1H, J =8.9, 2.4 Hz), 8.16 (d, 1H, J =2.4 Hz), 9.26 (s, 1H); ^{13}C NMR (100 MHz, DMSO- d_6) δ =51.7, 112.1, 115.9, 116.1, 119.8, 121.8, 122.1, 122.8, 124.0, 127.9, 129.0, 129.6, 130.1, 135.0, 145.8, 146.3, 148.1; HRMS (ESI) m/z $[M + H]^+$ calcd for $C_{17}H_{15}N_4O_3S$: 355.0865, found 355.0869.



1-(2,2-dioxido-3H-1,2-benzoxathiepin-7-yl)-1H-1,2,3-triazol-4-yl]methanol (16)

Compound **16** was prepared according to the general procedure from propargyl alcohol (0.012 ml, 0.21 mmol), azide **8** (50 mg,

0.21 mmol), $CuSO_4 \cdot 5H_2O$ (105 mg, 0.42 mmol), sodium ascorbate (166 mg, 0.84 mmol), AcOH (0.25 ml, 4.37 mmol) as white solid (50 mg, 81%). Mp 144–145 °C. IR (KBr, cm^{-1}) ν_{max} =1374 (S=O), 1167 (S=O); 1H NMR (400 MHz, DMSO- d_6) δ =4.59 (d, 2H, J =5.7 Hz), 4.62 (s, 2H), 6.05–6.13 (m, 1H), 6.98 (d, 1H, J =11.5 Hz), 7.56 (d, 1H, J =8.9 Hz), 7.99 (dd, 1H, J =8.9, 2.6 Hz), 8.09 (d, 1H, J =2.6 Hz), 8.74 (s, 1H); ^{13}C NMR (100 MHz, DMSO- d_6) δ =51.8, 54.9, 121.3, 121.5, 121.9, 122.6, 123.9, 129.5, 130.1, 135.1, 146.1, 149.4; HRMS (ESI) m/z $[M + H]^+$ calcd for $C_{12}H_{12}N_3O_4S$: 294.0549, found 294.0553.




4-(2,2-Dioxido-3H-1,2-benzoxathiepin-7-yl)-1-[4-(trifluoromethyl)phenyl]-1H-1,2,3-triazole (17)

Compound **17** was prepared according to the general procedure from 4-(trifluoromethyl)phenylacetylene (36 mg, 0.21 mmol), azide **8** (50 mg, 0.21 mmol), $CuSO_4 \cdot 5H_2O$ (105 mg, 0.42 mmol), sodium ascorbate (166 mg; 0.84 mmol), AcOH (0.25 ml, 4.37 mmol) as yellowish solid (73 mg, 85%). Mp 192–193 °C. IR (KBr, cm^{-1}) ν_{max} =1358 (S=O), 1328 (S=O), 1174 (S=O), 1166 (S=O); 1H NMR (400 MHz, DMSO- d_6) δ =4.62 (dd, 2H, J =5.9, 1.0 Hz), 6.09–6.16 (m, 1H), 7.01 (d, 1H, J =11.5 Hz), 7.64 (d, 1H, J =8.8 Hz), 7.86–7.91 (m, 2H), 8.04 (dd, 1H, J =8.8, 2.7 Hz), 8.13 (d, 1H, J =2.7 Hz), 8.13–8.18 (m, 2H), 9.52 (s, 1H); ^{13}C NMR (100 MHz, DMSO- d_6) δ =51.7, 121.2, 121.7, 122.1, 122.8, 124.1, 124.2 (q, J =272.0 Hz), 125.8, 126.1 (q, J =3.8 Hz), 128.4 (q, J =32.0 Hz), 129.6, 130.0, 134.0, 134.9, 146.0, 146.4; HRMS (ESI) m/z $[M + H]^+$ calcd for $C_{18}H_{13}F_3N_3O_3S$: 408.0630, found 408.0626.

CA inhibition assay

An SX.18 MV-R Applied Photophysics (Oxford, UK) stopped-flow instrument has been used to assay the catalytic/inhibition of various CA isozymes¹⁶. Phenol Red (at a concentration of 0.2 mM) has been used as indicator, working at the absorbance maximum of 557 nm, with 10 mM Hepes (pH 7.4) as buffer, 0.1 M Na_2SO_4 or $NaClO_4$ (for maintaining constant the ionic strength; these anions are not inhibitory in the used concentration),¹⁷ following the CA-catalysed CO_2 hydration reaction for a period of 5–10 s. Saturated CO_2 solutions in water at 25 °C were used as substrate. Stock solutions of inhibitors were prepared at a concentration of 10 mM (in DMSO-water 1:1, v/v) and dilutions up to 1 nM done with the assay buffer mentioned above. At least seven different inhibitor concentrations have been used for measuring the inhibition constant. Inhibitor and enzyme solutions were preincubated together for 6 h at 4 °C prior to assay, in order to allow for the formation of the E-I complex. Triplicate experiments were done for each inhibitor concentration, and the values reported throughout the paper are the mean of such results. The inhibition constants were obtained by non-linear least-squares methods using the Cheng-Prusoff equation, as reported earlier¹⁷, and represent the mean from at least three different determinations. All CA isozymes used here were recombinant proteins obtained as reported earlier by our group¹⁸.



Scheme 2. Reagents and conditions: (i) MePPh₃Br, tBuOK, THF, RT, 24 h; (ii) NEt₃, CH₂Cl₂, RT, 20 h; (iii) **5**, toluene, 70 °C, 4 h; (iv) Fe, AcOH, EtOH, H₂O, 70 °C, 1 h, 98%; (v) 1) NaNO₂, H₂O, TFA, 2) NaN₃, H₂O, 69%; (vi) alkyne, tBuOH/H₂O (1:1), CuSO₄, sodium ascorbate, acetic acid, 30 min.

X-ray structure determination

X-Ray diffraction data for compound **6c** were collected using a *NoniusKappaCCD* diffractometre (MoK α radiation, $\lambda = 0.71073 \text{ \AA}$), equipped with low temperature *Oxford CryosystemsCryostream Plus* device (Delft, the Netherlands). Data were collected using *KappaCCD Server Software*, cell refined by *SCALEPACK*¹⁹, data reduction performed by *DENZO*²⁰ and *SCALEPACK*¹⁹, structures solved by direct method using *SIR2004* and refined by *SHELXL97*²¹ as implemented in the program package *WinGX*²². Software used to prepare CIF file was *SHELXL97*²¹ and *graphics-ORTEP3*²².

Crystal data for 6c: C₉H₇NO₅S ($M = 241.22$), monoclinic, $P2_1/a$, $a = 7.3194(3)$, $b = 14.9000(7)$ and $c = 18.3387(8) \text{ \AA}$, $\beta = 101.325(1)^\circ$, $V = 1961.06(15) \text{ \AA}^3$, $T = 173(2) \text{ K}$, $Z = 2$, $Z' = 1$, $\mu(\text{MoK}\alpha) = 0.34 \text{ mm}^{-1}$, 9545 reflections measured, 2150 independent reflections ($R_{\text{int}} = 0.083$), $R_1(\text{obs}) = 0.058$, $wR1(\text{obs}) = 0.1500$, $R_1(\text{all}) = 0.1893$, $wR1(\text{all}) = 0.1096$, $S = 0.94$.

CCDC 1526002 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via <http://www.ccdc.cam.ac.uk>.

Results and discussion

Chemistry

The synthesis of homo-sulfocoumarins began with a Wittig reaction in which salicylic aldehydes **1** were converted to the corresponding mono-olefins **2a–c** in good yields (Scheme 2). Treatment of compounds **2a–c** with allyl sulfanyl chloride (**3**) provided bis-olefins **4a–c** as the key intermediates, again in good yields

(see Experimental for details). In the next step, olefin metathesis with the commercially available Ru-catalyst **5** was used, in which bis-olefins **4a–c** were converted to 3H-1,2-benzoxathiepine 2,2-dioxides **6a–b** in 84–96% yields. To obtain a series of 7-substituted homo-sulfocoumarins, the synthesis of 1,4-triazolyl derivatives **9–17** was thereafter performed. For this purpose, 7-nitro derivative **6c** was reduced by elemental iron to the corresponding amine **7** in nearly quantitative yield. Further diazotation of amine **7** followed by *in situ* treatment with sodium azide afforded the azide **8**. Treatment of azide **8** with alkynes under click chemistry condition provides a series of 1,4-triazolyl homo-sulfocoumarins **9–17** in good to excellent yields (see Experimental for details).

The structures of all synthesized 3H-1,2-benzoxathiepine 2,2-dioxides **6–17** were fully supported by ¹H, ¹³C NMR and IR spectroscopy, MS or elemental analysis. Additionally, the final unequivocal identification of the scaffold of 3H-1,2-benzoxathiepine 2,2-dioxide was established by a single-crystal X-ray structure for compound **6c**, shown in Figure 2.

Carbonic anhydrase inhibition

All the synthesized derivatives **6c–17** were evaluated for their efficacy in inhibiting four relevant CA isoforms, i.e. hCA I, II, IX and XII, by using the stopped flow carbon dioxide hydrase assay¹⁶, in comparison to the sulphonamide acetazolamide (**AAZ**, 5-acet-amido-1,3,4-thiadiazole-2-sulfonamide) as a standard CAI.

Data of Table 1 show that the cytosolic isoforms hCA I and II (widely distributed enzymes, with important physiological roles in many tissues)^{9,10} were generally not inhibited by the investigated homo-sulfocoumarins, up to 50 μM concentration of inhibitors in




Figure 2. Single-crystal X-ray structure of **6c** (CCDC deposition number 1526002). Thermal ellipsoids are drawn at the 50% probability level (see Experimental for details).

Table 1. CA inhibition data against isoforms hCA I, II, IX and XII with homo-sulfocoumarins **6–17** and acetazolamide (AAZ) as standard, by a stopped-flow CO₂ hydrase assay¹⁴.

Compound	K _i (μM) ^a			
	hCA I	hCA II	hCA IX	hCA XII
6c	>50	>50	0.027	0.64
7	>50	>50	3.57	>50
9	>50	>50	1.71	>50
10	>50	>50	3.59	>50
11	>50	>50	2.56	>50
12	>50	>50	1.75	>50
13	>50	5.77	0.34	1.72
14	>50	>50	1.15	>50
15	>50	>50	0.46	2.32
16	>50	>50	0.87	>50
17	>50	>50	0.43	>50
AAZ	0.25	0.012	0.025	0.006

^aErrors in the range of ±5% of the reported values, from three different assays.

the assay system. Only one derivative, **13**, showed a moderate inhibitory profile against hCA II, with an inhibition constant of 5.77 μM.

The tumour associated isoform hCA IX, a validated drug target for antitumor/antimetastatic agents^{23,24}, was on the other hand effectively inhibited by the investigated homo-sulfocoumarins, with K_is ranging between 27 nM and 3.59 μM (Table 1). The structure activity relationship (SAR) was very interesting, as the best inhibitor (**6c**) incorporated a compact, powerful electron attracting moiety (NO₂) whereas the remaining derivatives, incorporating substituted 1,2,3-triazole moieties in position 7 of the homo-sulfocoumarin ring were less effective hCA IX inhibitors. Four submicromolar hCA IX inhibitors were however detected apart **6c**, derivatives **13**, **15**, **16** and **17**, which incorporate either the compact hydroxymethyl group at the triazole fragment of the molecule, or substituted phenyls with 4-trifluoromethoxy-, 2-amino-, or 4-trifluoromethyl substituents on the aryl fragment. These derivatives showed K_is ranging between 0.34 and 0.87 μM. The remaining homo-sulfocoumarins were low micromolar hCA IX inhibitors.

The SAR for inhibition of the second tumour-associated isoform, hCA XII, was more complex compared to what discussed above for hCA IX (Table 1). Thus, 8 out of 11 derivatives were inactive (K_is > 50 μM) whereas the remaining ones, **6c**, **13** and **15**, inhibited hCA XII with K_is in the range of 0.64–2.32 μM.

This inhibition profile is rather similar to the one of sulfocoumarins^{1–6} and coumarins^{7,8}, which are generally selective inhibitors for the tumour-associated over the cytosolic isoforms. However, some homo-sulfocoumarins showed a very specific, and unique up until now inhibition profile among all classes of CAIs known to

date^{9,10}, as they are highly selective for hCA IX over hCA I, II and XII (e.g. **7–12**, **14**, **16** and **17**).

In conclusion, we report here a new chemotype with effective and isoform-selective CAIs, the homo-sulfocoumarins, which show a unique inhibition profile for the tumour-associated CA isoforms hCA IX (and XII) over the cytosolic ones. Although the CA inhibition mechanism with these new compounds is unknown for the moment, we hypothesize that it may be similar to that of the sulfocoumarins, i.e. hydrolysis to the corresponding sulfonic acids which thereafter anchor to the zinc-coordinated water molecule within the enzyme active site.

Disclosure statement

No potential conflict of interest was reported by the authors.

References

1. a) Grandane A, Belyakov S, Trapencieris P, et al. Facile synthesis of coumarin bioisosteres – 1,2-benzoxathiine 2,2-dioxides. *Tetrahedron* 2012;68:5541–6. b) Tars K, Vullo D, Kazaks A, et al. Sulfocoumarins (1,2-benzoxathiine-2,2-dioxides): a class of potent and isoform-selective inhibitors of tumor-associated carbonic anhydrases. *J Med Chem* 2013; 56:293–300.
2. Tanc M, Carta F, Bozdog M, et al. 7-Substituted-sulfocoumarins are isoform-selective, potent carbonic anhydrase II inhibitors. *Bioorg Med Chem* 2013;21:4502–10.
3. a) Grandane A, Tanc M, Zalubovskis R, et al. Synthesis of 6-tetrazolyl-substituted sulfocoumarins acting as highly potent and selective inhibitors of the tumor-associated carbonic anhydrase isoforms IX and XII. *Bioorg Med Chem* 2014;22:1522–8. b) Grandane A, Tanc M, Zalubovskis R, et al. 6-Triazolyl-substituted sulfocoumarins are potent, selective inhibitors of the tumor-associated carbonic anhydrases IX and XII. *Bioorg Med Chem Lett* 2014;24:1256–60.
4. Grandane A, Tanc M, Di Cesare Mannelli L, et al. 6-Substituted sulfocoumarins are selective carbonic anhydrase IX and XII Inhibitors with significant cytotoxicity against colorectal cancer cells. *J Med Chem* 2015;58: 3975–83.
5. Grandane A, Tanc M, Zalubovskis R, et al. Synthesis of 6-aryl-substituted sulfocoumarins and investigation of their carbonic anhydrase inhibitory action. *Bioorg Med Chem* 2015;23:1430–6.
6. Nocentini A, Ceruso M, Carta F, et al. 7-Aryl-triazolyl-substituted sulfocoumarins are potent, selective inhibitors of the tumor-associated carbonic anhydrase IX and XII. *J Enzyme Inhib Med Chem* 2016;31:1226–33.
7. (a) Maresca A, Temperini C, Vu H, et al. Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. *J Am Chem Soc* 2009;131:3057–62. b) Maresca A, Temperini C, Pochet L, et al. Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. *J Med Chem* 2010;53:335–44. c) Maresca A, Supuran CT. Coumarins incorporating hydroxy- and chloro-moieties selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic ones I and II. *Bioorg Med Chem Lett* 2010;20:4511–14.
8. a) Maresca A, Scozzafava A, Supuran CT. 7,8-Disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the

- transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic ones I and II in the low nanomolar/subnanomolar range. *Bioorg Med Chem Lett* 2010;20:7255–58. b) Touisni N, Maresca A, McDonald PC, et al. Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors. *J Med Chem* 2011;54:8271–7. c) Carta F, Maresca A, Scozzafava A, et al. Novel coumarins and 2-thioxo-coumarins as inhibitors of the tumor-associated carbonic anhydrases IX and XII. *Bioorg Med Chem* 2012;20:2266–73. d) Davis RA, Vullo D, Maresca A, et al. Natural product coumarins that inhibit human carbonic anhydrases. *Bioorg Med Chem* 2013;21:1539–43. e) Sharma A, Tiwari M, Supuran CT. Novel coumarins and benzocoumarins acting as isoform-selective inhibitors against the tumor-associated carbonic anhydrase IX. *J Enzyme Inhib Med Chem* 2014;29:292–6. f) Ferraroni M, Carta F, Scozzafava A, Supuran CT. Thioxocoumarins show an alternative carbonic anhydrase inhibition mechanism compared to coumarins. *J Med Chem* 2016;59:462–73.
9. a) Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. *Nat Rev Drug Discov* 2008;7:168–81. b) Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. *Nat Rev Drug Discov* 2011;10:767–77. c) Durdagi S, Vullo D, Pan P, et al. Protein-protein interactions: Inhibition of mammalian carbonic anhydrases I–XV by the murine inhibitor of carbonic anhydrase and other members of the transferrin family. *J Med Chem* 2012;55:5529–35. d) Di Cesare Mannelli L, Micheli L, Carta F, et al. Carbonic anhydrase inhibition for the management of cerebral ischemia: in vivo evaluation of sulfonamide and coumarin inhibitors. *J Enzyme Inhib Med Chem* 2016;31:894–9.
 10. a) Supuran CT. Structure and function of carbonic anhydrases. *Biochem J* 2016;473:2023–32. b) Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? *J Enzyme Inhib Med Chem* 2016;31:345–60. c) Supuran CT. Carbonic anhydrases. *Bioorg Med Chem* 2013;21:1377–8. d) Supuran CT. Advances in structure-based drug discovery of carbonic anhydrase inhibitors. *Expert Opin Drug Discov* 2017;12:61–88. e) Alterio V, Di Fiore A, D'Ambrosio K, et al. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? *Chem Rev* 2012;112:4421–68. f) Supuran CT. *Legionella pneumophila* carbonic anhydrases: underexplored antibacterial drug targets. *Pathogens* 2016;5:E44.
 11. (a) De Simone G, Alterio V, Supuran CT. Exploiting the hydrophobic and hydrophilic binding sites for designing carbonic anhydrase inhibitors. *Expert Opin Drug Discov* 2013;8:793–810. (b) Masini E, Carta F, Scozzafava A, et al. Antiglaucoma carbonic anhydrase inhibitors: a patent review. *Expert Opin Ther Pat* 2013;23:705–16. (c) Supuran CT. Carbonic anhydrase inhibitors. *Bioorg Med Chem Lett* 2010;2:3467–74. (d) Supuran CT. Carbonic anhydrases: from biomedical applications of the inhibitors and activators to biotechnological use for CO₂ capture. *J Enzyme Inhib Med Chem* 2013;28:229–30. e) D'Ambrosio K, Carradori S, Monti SM, et al. Out of the active site binding pocket for carbonic anhydrase inhibitors. *Chem Commun* 2015;51:302–5.
 12. a) Supuran CT. Structure-based drug discovery of carbonic anhydrase inhibitors. *J Enzyme Inhib Med Chem* 2012;27:759–72. b) Supuran CT. Carbonic anhydrase inhibitors: an editorial. *Expert Opin Ther Pat* 2013;23:677–9. c) Winum JY, Supuran CT. Recent advances in the discovery of zinc-binding motifs for the development of carbonic anhydrase inhibitors. *J Enzyme Inhib Med Chem* 2015;30:321–4. d) De Luca V, Del Prete S, Supuran CT, et al. Protonography, a new technique for the analysis of carbonic anhydrase activity. *J Enzyme Inhib Med Chem* 2015;30:277–82. e) Lomelino CL, Supuran CT, McKenna R. Non-classical inhibition of carbonic anhydrase. *Int J Mol Sci* 2016;17:E1150.
 13. a) Supuran CT. Acetazolamide for the treatment of idiopathic intracranial hypertension. *Expert Rev Neurother* 2015;15:851–6. b) Di Fiore A, De Simone G, Alterio V, et al. The anticonvulsant sulfamide JNJ-26990990 and its: S,S-dioxide analog strongly inhibit carbonic anhydrases: solution and X-ray crystallographic studies. *Org Biomol Chem* 2016;14:4853–8. c) Supuran CT. Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors. *Expert Opin Drug Metab Toxicol* 2016;12:423–31.
 14. Albert S, Horbach R, Deising HB, et al. Synthesis and antimicrobial activity of (E) stilbene derivatives. *Bioorg Med Chem* 2011;19:5155–66.
 15. Dauban P, Dodd RH. Synthesis of cyclic sulfonamides via intramolecular copper-catalyzed reaction of unsaturated iminoiodinanes. *Org Lett* 2000;2:2327–9.
 16. Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. *J Biol Chem* 1971;246:2561–73.
 17. Leitans J, Sprudza A, Tanc M, et al. 5-Substituted-(1,2,3-triazol-4-yl)thiophene-2-sulfonamides strongly inhibit human carbonic anhydrases I, II, IX and XII: solution and X-ray crystallographic studies. *Bioorg Med Chem* 2013;21:5130–8.
 18. a) Korkmaz N, Obaidi OA, Senturk M, et al. Synthesis and biological activity of novel thiourea derivatives as carbonic anhydrase inhibitors. *J Enzyme Inhib Med Chem* 2015;30:75–80. b) Abdel-Aziz AAM, El-Azab AS, Ekinci D, et al. Investigation of arenesulfonyl-2-imidazolidinones as potent carbonic anhydrase inhibitors. *J Enzyme Inhib Med Chem* 2015;30:81–4. c) Akdemir A, De Monte C, Carradori S, et al. Computational investigation of the selectivity of salen and tetrahydrosalen compounds towards the tumor-associated hCA XII isozyme. *J Enzyme Inhib Med Chem* 2015;3:114–18. d) Leitans J, Kazaks A, Balode A, et al. Efficient expression and crystallization system of cancer-associated carbonic anhydrase isoform IX. *J Med Chem* 2015;58:9004–9. e) Göçer H, Akincioğlu AS, Gülçin GI, et al. Carbonic anhydrase and acetylcholinesterase inhibitory effects of carbamates and sulfamoylcarbamates. *J Enzyme Inhib Med Chem* 2015;30:316–20. f) Ceruso M, Bragagni M, AlOthman Z, et al. New series of sulfonamides containing amino acid moiety act as effective and selective inhibitors of tumor-associated carbonic anhydrase XII. *J Enzyme Inhib Med Chem* 2015;3:430–4. g) Zolfaghari Emameh R, Syrjänen L, Barker H, et al. *Drosophila melanogaster*: a model organism for controlling dipteran vectors and pests. *J Enzyme Inhib Med Chem* 2015;30:505–13.
 19. Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. *Methods Enzymol* 1997;276:307–26.
 20. Burla MC, Caliandro R, Camalli M, et al. SIR2004: an improved tool for crystal structure determination and refinement. *J Appl Crystallogr* 2005;38:381–8.
 21. Sheldrick GM. A short history of SHELX. *Acta Crystallogr* 2008;64:112–22.
 22. Farrugia LJ. WinGX and ORTEP for windows: an update. *J Appl Crystallogr* 2012;45:849–54.

23. a) Gieling RG, Babur M, Mamnani L, et al. Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts. *J Med Chem* 2012;55:5591–600. b) Winum JY, Maresca A, Carta F, et al. Polypharmacology of sulfonamides: pazopanib, a multitargeted receptor tyrosine kinase inhibitor in clinical use, potently inhibits several mammalian carbonic anhydrases. *Chem Commun* 2012;48:8177–9. c) Lock EF, McDonald PC, Lou Y, et al. Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche. *Oncogene* 2013;32:5210–19. d) Ward C, Langdon SP, Mullen P, et al. New strategies for targeting the hypoxic tumour microenvironment in breast cancer. *Cancer Treat Rev* 2013;39:171–9.
24. a) Pan J, Lau J, Mesak F, et al. Synthesis and evaluation of ¹⁸F-labeled carbonic anhydrase IX inhibitors for imaging with positron emission tomography. *J Enzyme Inhib Med Chem* 2014;29:249–55. b) Pettersen EO, Ebbesen P, Gieling RG, et al. Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: The METOXIA consortium. *J Enzyme Inhib Med Chem* 2015;30:689–721.